

REMARKS

The amendments to the claims are supported by the instant specification and the disclosure of Priority Application Serial No. 08/465,968, filed June 6, 1995 (now U.S. Patent No. 6,608,182) and do not add new matter. Specifically, support for the language: "a method for stimulating tyrosine kinase activity of a receptor that binds VEGF-2" can be found in the instant specification, for example, at page 8, lines 17-18 (VEGF-2 is structurally related to the VEGF/PDGF family) and page 2, lines 5-7 (VEGF and PDGF function as homo-dimers or hetero-dimers and bind to receptors which elicit intrinsic tyrosine kinase activity following receptor dimerization). Similarly, support can be found in the Priority Application, for example, at page 2, second full paragraph and page 7, last paragraph. Support for the language "a method for promoting growth of endothelial cells that express a tyrosine receptor that binds VEGF-2" can be found in the specification, for example, at page 8, lines 17-18 (VEGF-2 is structurally related to the VEGF/PDGF family); page 2, lines 5-7 (VEGF and PDGF function as homo-dimers or hetero-dimers and bind to receptors which elicit intrinsic tyrosine kinase activity following receptor dimerization); and page 60, lines 23-26 and Examples 5 and 6 (VEGF-2 promotes the growth of endothelial cells). Similarly, support can be found in the Priority Application, for example, at page 2, second full paragraph; page 7, last paragraph; page 20, second full paragraph, and Examples 4 and 5. Support for "a polypeptide having at least 95% identity to a polypeptide comprising amino acid residues 23-419 of SEQ ID NO:2" can be found in the instant specification, for example, at page 7, lines 16-27 (the invention provides a VEGF-2 polypeptide having the amino acid sequence of SEQ ID NO:2 or encoded by the cDNA in ATCC Deposit No. 97149); page 4, lines 30-33 (VEGF-2 comprises approximately 419 amino acids of which approximately 23 represent the leader sequence); and page 38, lines 14-20 (polypeptides of the invention includes polypeptides which have at least 95% identity to the polypeptide of SEQ ID NO:2). Similarly, support can be found in the Priority Application, for example, at page 7, fourth and fifth paragraphs; and page 13, last paragraph. Thus, no new matter is added by the amendments to the claims.


CONCLUSION

Applicants believe that this application is in condition for allowance, and an early notice to that effect is earnestly solicited. The Examiner is invited to call the undersigned at the phone number provided below if any further action by Applicant would expedite the examination of this application.

If there are any fees due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 08-3425. If a fee is required for an extension of time under 37 C.F.R. § 1.136, such an extension is requested and the appropriate fee should also be charged to our Deposit Account.

Dated: May 7 2004

Respectfully submitted,

By 

Melissa J. Pytel

Registration No.: 41,512

HUMAN GENOME SCIENCES, INC.

14200 Shady Grove Road

Rockville, Maryland 20850

(301) 610-5764

MMW/MJP/ba